Dexmedetomidine (DEX) is a Alpha-2 specific agonist, is a common ICU sedation medication. In brain tumor resection craniotomy, it is proven to be effective in improving postoperative hypertension and tachycardia, mitigates postoperative nausea and vomiting and relives postoperative pain. In addition, many animal experiments show that DEX inhibits the proapoptosis in the mitochondrial in vivo and therefore avoids neuronal injury. It is also reported to be neuroprotective to isoflurane-induced neurotoxicity and to improve cerebral focal ischemic region (penumbra). However, the neuroprotective effects were never investigated clinically in patients undergoing brain tumor resection surgery.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Enrollment
160
Intraoperative dexmedetomidine infusion
National Taiwan University Hospital
Taipei, Taiwan
Number of participants with postoperative neurological complications
Time frame: during postoperative period of hospital admission, approximately 10 days by estimation
Number of participants with postoperative delirium
Time frame: during postoperative period of hospital admission, approximately 10 days by estimation
Serum biomarkers changes
biomarkers related to neuroinflammation and neuronal injury, such as HMGB1 and GFAP
Time frame: Between preoperative baseline and postoperative day one.
Intraoperative haemodynamic profile
Time frame: during intraoperative perioid, approximately 4-6 hours by estimation
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.